SCHEMBL3365025

SCHEMBL3365025

CCCc1ccc(S(=O)(=O)N(CC(=O)NN=C2C(=O)Nc3ccccc32)c2ccc(Cl)cc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OXTR P30559 5/20 0.49
AVPR1A P37288 3/20 0.49
ALDH1A1 P00352 6/20 0.43
MAPT P10636 1/20 0.43
HPGD P15428 1/20 0.43
PTGER1 P34995 2/20 0.42
KDM4E B2RXH2 3/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA4 P22748 1/20 0.41
CA7 P43166 1/20 0.41
RAB9A P51151 2/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365022 1.00 OXTR (0.49) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL3366503 0.92 ALDH1A1 (0.48) OXTRAVPR1AALDH1A1MAPTPTGER1
SCHEMBL3366497 0.92 ALDH1A1 (0.48) OXTRAVPR1AALDH1A1MAPTPTGER1
SCHEMBL3366411 0.90 MEN1 (0.51) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL3366414 0.90 MEN1 (0.51) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL5641723 0.90 MEN1 (0.51) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL3365642 0.90 OXTR (0.54) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL3365636 0.90 OXTR (0.54) OXTRAVPR1AALDH1A1MAPTHPGD
SCHEMBL3365077 0.88 OXTR (0.52) OXTRAVPR1AALDH1A1MAPTKDM4E
SCHEMBL3365082 0.88 OXTR (0.52) OXTRAVPR1AALDH1A1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP claimed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US claimed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US claimed
EP-1335901-B1 PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES MERCK SERONO SA (CH) 2010-04-14 EP disclosed
US-7312358-B2 Pharmaceutically active sulfanilide derivatives LABORATOIRES SERONO SA (CH) 2007-12-25 US disclosed
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives MERCK SERONO SA (CH) 2004-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072816-A1 Pharmaceutically active sulfanilide derivatives OXTR, AVPR2, OPRL1 OXTR 1/4885AVPR1A 4/4885ALDH1A1 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.